Clinical Trials Logo
  1. Home
  2. Cervical Neoplasm
  3. NCT03418480

HARE-40: HPV Anti-CD40 RNA vaccinE — HARE-40  

Head and Neck Neoplasm Clinical Trial

Official title:
Therapeutic HPV Vaccine (BNT113) Trial in HPV16 Driven Carcinoma

Clinical Trial Summary

HARE-40 is a phase I/II vaccine dose escalation study with two different arms: Arm 1A will perform intrapatient dose escalation in patients with previously treated HPV16+ Head & Neck Cancer using two dose cohorts to establish a safe, tolerable and recommended dose of HPV vaccine. Arm 1B will perform intrapatient dose escalation in patients with advanced HPV16+ cancer (head and neck, anogenital, penile, cervical and other) using a single cohort to establish a safe, tolerable and recommended dose of HPV vaccine.

Clinical Trial Description

HARE-40 is a phase I/II vaccine dose escalation trial with two arms (Arm 1A and Arm 1B) in which we will test BNT113 as monotherapy. We will undertake a multi-centre phase I, open label trial in patients with previous HPV16+ HNSCC without current clinical evidence of disease (Arm 1A) and in patients with HPV16+ advanced disease (Arm 1B). The HPV16 antigen-specific immune response will be evaluated before and after treatment in circulating blood and, where samples have been collected, in tumour and skin biopsies. Arms 1A and 1B will escalate BNT113 in each patient (intrapatient dose escalation) up to the specified target dose of the cohort to establish a safe, tolerable and recommended dose of BNT113 in patents who are disease free (Arm 1A) and those with advanced disease (Arm 1B). Subset of patients in Arm 1B will also be assessed for response to the vaccine in terms of a significant increase of immune cells following BNT113 administration and according to irRECIST1.1 (all 29 patients including the expansion cohort) and other endpoints. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03418480
Study type Interventional
Source University of Southampton
Contact
Status Completed
Phase Phase 1/Phase 2
Start date April 11, 2017
Completion date January 24, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT02960308 - Whole-Neck Computed Tomography Perfusion Scan in Imaging Patients With Head and Neck Tumors
Terminated NCT02602067 - 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients Phase 1
Completed NCT04277273 - Characteristics of a Maxillofacial Prosthesis Consultation Within Assistance Publique - Hopitaux de Paris N/A
Completed NCT03896906 - Preoxygenation With a High-flow Nasal Cannula or a Simple Mask Before General Anesthesia in Head and Neck Surgery N/A
Completed NCT01621295 - Assessing the Patient Experience in Cancer Care N/A
Active, not recruiting NCT03854838 - IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma. Phase 2
Completed NCT04151030 - Endoscopic Direct-PEG Placement in Patients Unable to Undergo Pull-PEG Procedure N/A
Completed NCT03012581 - Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types Phase 2
Active, not recruiting NCT04005521 - Randomized Study Regarding Preventive Jaw- and Swallowing Intervention for Patients With Head and Neck Cancer N/A
Recruiting NCT05011500 - Masks Against Surface-Scanning for Radiation Therapy Immobilisation in Head and Neck Cancer (MASSC) N/A
Completed NCT05590650 - A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients Phase 1
Terminated NCT03402737 - SBRT + Immunomodulating Systemic Therapy for Inoperable, Recurrent H&N N/A
Completed NCT04086849 - Analysis of Patterns of Recurrence in Head and Neck Cancer Using Clinicopathomic Markers
Completed NCT00001442 - A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer Phase 1
Recruiting NCT04477759 - Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer Phase 1
Terminated NCT00423150 - Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED) Phase 2
Recruiting NCT03757091 - Flexible Intubation Scope With or Without Video Laryngoscope in Supporting Endotracheal Tube Placement in Patients With Head and Neck Cancer Before Surgery N/A
Recruiting NCT04099290 - Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma
Withdrawn NCT04679233 - Feasibility and Safety of Aerobic Exercise for Head and Neck Cancer Patients N/A
Not yet recruiting NCT04267627 - Telemedicine Nurse-Led Intervention for Rural Cancer Survivors N/A